Artwork
iconShare
 
Manage episode 517580846 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:

  • Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)
  • Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)
  • Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)
  • Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)
  • Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34)
  • Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16)
  • Case: Patient with ER-positive, HER2-negative breast cancer receives camizestrant after first-line tamoxifen (36:20)
  • Case: Patient with ER-positive, HER2-negative breast cancer receives elacestrant after disease progression on first-line letrozole/palbociclib (38:11)

CME information and select publications

  continue reading

867 episodes